Posted by Michael Wonder on 15 Nov 2022
FDA grants accelerated approval to mirvetuximab soravtansine-gynx for folate receptor alfa positive, platinum resistant epithelial ovarian, fallopian tube, or peritoneal cancer
14 November 2022 - Today the FDA granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere, ImmunoGen) for adult patients with folate receptor alfa positive, platinum resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Mirvetuximab soravtansine-gynx is a folate receptor alfa directed antibody and microtubule inhibitor conjugate. Patients are selected for therapy based on an FDA approved test.
